表紙
市場調査レポート

ヒストンデアセチラーゼ阻害剤:新興市場

Histone Deacetylase Inhibitors: Emerging Markets

発行 BCC Research 商品コード 296551
出版日 ページ情報 英文 153 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
ヒストンデアセチラーゼ阻害剤:新興市場 Histone Deacetylase Inhibitors: Emerging Markets
出版日: 2014年02月24日 ページ情報: 英文 153 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のヒストンデアセチラーゼ阻害剤(HDI)市場は、2011年に1億5300万米ドル、2012年に2億2320万米ドルに達しました。同市場は2013年から2018年間にCAGR21.4%で拡大し、市場額は2013年の3億6,180万米ドルから2018年に9億5,430万米ドルに達すると予測されています。

当レポートでは、世界のヒストンデアセチラーゼ阻害剤(HDI)市場について調査し、世界市場の動向、実績データ・推計・CAGR予測、地域・アプリケーション別の市場分析、主要HDI企業のプロファイルなどをまとめ、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • ヒストン脱アセチル化酵素とヒストンアセチラーゼ
  • ヒストンデアセチラーゼ阻害剤(HDI)
  • 分類
  • その他のヒストンデアセチラーゼ阻害剤(HDI)
  • 非ヒストンタンパク質のアセチル化
  • 新しい標的

第4章 規制側面

  • VORINOSTAT
  • ROMIDEPSIN
  • ヒストンデアセチラーゼ阻害剤(HDI)の規制発展

第5章 新たな開発

  • 新たな共同試験・将来の活動

第6章 ヒストンデアセチラーゼ阻害剤(HDI)の市場分析

  • 市場:タイプ別
  • 市場:地域別
  • 将来市場の予測
  • 産業構造

第7章 市場:アプリケーション別

  • 市場:アプリケーション別
  • 将来のアプリケーション
  • 研究開発

第8章 特許分析

  • 年度別
  • ヒストンデアセチラーゼ阻害剤(HDI)の分類別
  • ヒストンデアセチラーゼ阻害剤(HDI)の種類別
  • 国別
  • 企業別
  • 出願者別

第9章 現況

  • 研究・前進
  • ヒストンデアセチラーゼ開発における新技術・プラットフォーム
  • ヒストンデアセチラーゼ市場の影響因子
  • ヒストンデアセチラーゼ市場の現在の促進因子
  • コラボレーション・買収

第10章 企業プロファイル

第11章 略語

図表リスト

目次
Product Code: PHM163A

The global histone deacetylase inhibitor (HDI) market reached $153 million in 2011 and $223.2 million in 2012. This market is expected to be valued at $361.8 million in 2013 and $954.3 million by 2018, a compound annual growth rate (CAGR) of 21.4%.

This report provides:

  • An overview of the global market for histone deacetylase inhibitors.
  • Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of CAGRs through 2018.
  • A breakdown of the market for histone deacetylase inhibitors not only by region, but by application as well.
  • Information pertaining to the manufacturing of HDIs as well information on the manufacturing companies involved.
  • Profiles of leading HDI companies in the market.

REPORT SCOPE

INTRODUCTION

STUDY OBJECTIVES

The objective of this BCC Research study was to evaluate, analyze and predict the prospective histone deacetylase inhibitors (HDIs) market, as well as the progress of the ongoing clinical developments of numerous candidates. The report portrays the present HDI niche market and projects a provisional picture of future market escalation derived from the current products, the impressive HDI pipelines, successful research and development activities, the strategic plans of larger biopharmaceuticals and pharmaceuticals, and the present and prospective market dynamics.

The report presents a holistic view on the present market size based on the two approved HDI products: vorinostat (Zolinza) and romidepsin (Istodax). It also interprets the anticipated market size, revenue assessment, prospective products based on classic and second-generation histone deacetylase inhibitors, market leaders, market shares and the drivers shaping the HDIs market. An outline of the innovative platforms, technologies and prospective candidates for the present and potential market based on their potency in various diseases are detailed. It is too early to project the market trend from just two approved products, so the prospective market is presented in a summarized manner derived from the successful and promising clinical developments of late-stage products. The opportunities, limitations, patent analysis, new developments and regulatory aspects are detailed to the extent of the scope of this report. Profiles of reputed and budding companies involved in the development of HDIs are also provided.

The sales data for the two products is obtained from the relevant sources, including the manufacturing company's annual reports. The data is analyzed for the period from 2011 through October 2013. A 2018 revenue projection is also provided. The report analyzes the regional sales data for North America, which is comprised of the U.S. and Canada; Europe; and the emerging markets for this period.

REASONS FOR DOING THIS STUDY

Drugs that target epigenetic alterations have recently presented clinical potential, and histone deacetylase inhibitors comprised one such genre of drugs. The prospect of using histone deacetylase inhibitors in the treatment of cancer is already recognized through vorinostat and romidepsin. The potency and efficacy of these drugs and other candidates for various diseases, including cancer, heart ailments and human immunodeficiency virus (HIV) infection, are being investigated. The progress in the research and development (R&D) of the histone deacetylase inhibitors in recent years is significant. This report offers a synopsis of the latest exploratory work and market opportunities for the producers of HDIs from the viewpoint of new products, their prospective application on target diseases, the latest clinical developments and late-stage candidates. Furthermore, it provides details of scientific researches that would be helpful for scientists and research organizations for the advancement of their R&D work.

The present market dynamics including the prospective pipeline, collaboration and joint ventures, focused researches and most importantly the need of drugs for the fatal diseases such as cancer, neurodegenerative diseases and others are driving the activities in the histone deacetylase inhibitors space. There is enormous opportunity for this industry to develop and commercialize products for a huge patient base worldwide and this report presents the details meticulously.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This report accentuates two major aspects. One is the inevitability of histone deacetylase inhibitors to treat diseases, most of which currently have no proper cure. The other is the opportunity in a market that lacks very few commercialized products. There are currently only four drugs approved in the epigenetic drug market. This study presents the key developments of the histone deacetylase inhibitors industry that would be useful for the manufacturers, producers, researchers, research universities, and other government and non-government organizations.

SCOPE OF THE STUDY

BCC Research carried out the market assessment of the present niche market for histone deacetylase inhibitors, the geographic breakdown of sales data, current and prospective applications, regulatory aspects, market projection, advances and restraints, patent analysis, clinical developments, market leaders and market share for histone deacetylase inhibitors. The sales data for the global markets is authenticated for the present and anticipated values through statistical analysis. Correspondingly, regional data was measured for respective regions. The product and candidate information, technologies and platforms are based on their prospective application and practicability.

METHODOLOGY

BCC Research collected all pertinent information for this study through primary and secondary research methodologies. In the process, BCC Research interviewed industry experts, including producers of histone deacetylase inhibitors, scientists and other industry veterans. Searches were conducted in various information sources. Market projections echo the probable unit prices, usage of HDIs, the present-day economy and plausible HDI applications.

INFORMATION SOURCES

BCC Research investigated suitable companies and organizations related to the histone deacetylase inhibitor industry. These were primarily producers, research organizations and universities. Spokespersons for the companies and research teams were interviewed to obtain a better understanding of the prospective histone deacetylase inhibitors industry.

BCC Research also consulted scientific papers, pharmaceutical and other relevant newsletters; research papers and articles; digests; medical and pharmaceutical blogs; news feeds; science journals; medical papers and journals; company white papers; newsletters; company literature and financial reports; product literature; periodicals; abstracts; regulatory aspects; bulletins; technical articles; patent files; and pharmaceutical, biopharmaceutical and medicine-related databases.

Table of Contents

CHAPTER 1 INTRODUCTION 2

  • STUDY OBJECTIVES 2
  • REASONS FOR DOING THIS STUDY 2
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM 3
  • SCOPE OF THE STUDY 3
  • METHODOLOGY 3
  • INFORMATION SOURCES 3
  • ABOUT THE AUTHOR 4
  • RELATED BCC RESEARCH REPORTS 5
  • BCC RESEARCH ONLINE SERVICES 5
  • DISCLAIMER 5

CHAPTER 2 EXECUTIVE SUMMARY 7

  • SUMMARY TABLE GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 8
  • SUMMARY FIGURE GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, 2011-2018 ($ MILLIONS) 8

CHAPTER 3 OVERVIEW 11

  • HISTONE DEACETYLASES AND HISTONE ACETYLASES 11
  • HISTONE DEACETYLASE INHIBITORS 11
    • MECHANISM OF ACTION 11
    • APPROVED HISTONE DEACETYLASE INHIBITORS 12
    • FUTURE ACTIVITIES 12
  • CLASSIFICATION 13
    • HISTONE DEACETYLASES 13
    • TABLE 1 HISTONE DEACETYLASE CLASSIFICATION 13
    • HISTONE DEACETYLASE INHIBITORS 13
      • Classical Histone Deacetylase Inhibitors 14
        • Hydroxamic Acid 14
        • FIGURE 1 HYDROXAMIC ACID GENERAL STRUCTURE 15
          • Trichostatin A 15
          • FIGURE 2 TRICHOSTATIN A ACID STRUCTURE 15
        • Cyclic Tetrapeptides and Depsipeptides 16
          • Trapoxin B 16
          • FIGURE 3 TRAPOXIN B STRUCTURE 17
          • Romidepsin 17
          • FIGURE 4 ROMIDEPSIN STRUCTURE 17
        • Benzamides 18
        • FIGURE 5 BENZAMIDE STRUCTURE 18
        • Aliphatic Acid Compounds 18
          • Valproic Acid 18
          • FIGURE 6 VALPROIC ACID STRUCTURE 19
            • Sodium Valproate 19
            • FIGURE 7 SODIUM VALPROATE STRUCTURE 20
          • Phenylbutyrate 20
            • Sodium Phenylbutyrate 20
            • FIGURE 8 SODIUM PHENYLBUTERATE STRUCTURE 20
          • Butyrates 21
            • Sodium Butyrate 21
            • FIGURE 9 SODIUM BUTYRATE STRUCTURE 21
            • Pivanex 22
            • FIGURE 10 PIVANEX STRUCTURE 23
      • Second-Generation Histone Deacetylase Inhibitors 23
        • Hydroxamic Acid Derivatives 23
          • Vorinostat 23
          • FIGURE 11 VORINOSTAT STRUCTURE 23
          • Belinostat 24
          • FIGURE 12 BELINOSTAT STRUCTURE 25
          • Dacinostat 25
          • FIGURE 13 DACINOSTAT STRUCTURE 25
          • Panobinostat 26
          • FIGURE 14 PANOBINOSTAT STRUCTURE 26
          • Givinostat 26
          • FIGURE 15 GIVINOSTAT STRUCTURE 26
          • Pracinostat 27
          • FIGURE 16 PRACINOSTAT STRUCTURE 27
          • Abexinostat Hydrochlirode 28
          • FIGURE 17 ABEXINOSTAT STRUCTURE 28
          • Quisinostat 28
          • FIGURE 18 QUISINOSTAT STRUCTURE 29
          • Resminostat 29
          • FIGURE 19 RESMINOSTAT STRUCTURE 29
        • Benzamide Derivatives 30
          • Entinostat 30
          • FIGURE 20 ENTINOSTAT STRUCTURE 30
          • CI994 30
          • FIGURE 21 CI994 STRUCTURE 31
          • Mocetinostat 31
          • FIGURE 22 MOCETINOSTAT STRUCTURE 31
  • OTHER HISTONE DEACETYLASE INHIBITORS 32
  • ACETYLATION OF NON-HISTONE PROTEINS 32
  • EMERGING TARGETS 33
  • TABLE 2 EMERGING TARGETS FOR HISTONE DEACETYLASES INHIBITORS, BY HDI CLASS 33

CHAPTER 4 REGULATORY ASPECTS 42

  • VORINOSTAT 42
    • DOSING INFORMATION 42
      • Dose Modifications 43
    • SAFETY INFORMATION 43
      • Safety of Vorinostat in Specific Populations 44
  • ROMIDEPSIN 44
    • DOSING INFORMATION 44
      • Dose Modifications 44
        • Nonhematologic Toxicities Except Alopecia 44
        • Hematologic Toxicities 45
    • SAFETY INFORMATION 45
      • Safety of Romidepsin in Specific Populations 45
  • REGULATORY DEVELOPMENTS FOR HISTONE DEACETYLASE INHIBITORS 46

CHAPTER 5 NEW DEVELOPMENTS 50

  • TABLE 3 DEVELOPMENT STAGES FOR HISTONE DEACETYLASE INHIBITORS 51
  • TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES, OCTOBER 2013 52
  • TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS COMBINATION THERAPIES, OCTOBER 2013 54
  • TABLE 6 ONGOING TRIALS FOR MAJOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES AND COMBINATION THERAPIES, OCTOBER 2013 62
  • NEW COLLABORATIVE TRAILS AND FUTURE ACTIVITIES 63

CHAPTER 6 HISTONE DEACETYLASE INHIBITOR MARKET ANALYSIS 66

  • MARKET BY TYPE 67
  • TABLE 7 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY TYPE, THROUGH 2018 ($ MILLIONS) 67
  • FIGURE 23 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY TYPE, 2011-2018 ($ MILLIONS) 68
    • VORINOSTAT (ZOLINZA): HYDROXAMIC ACID DERIVATIVE 68
      • Market Overview 68
      • Market Revenue 69
      • TABLE 8 GLOBAL VORINSTAT MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 70
      • FIGURE 24 GLOBAL VORINSTAT MARKET BY REGION, 2011-2018 ($ MILLIONS) 70
    • ROMIDEPSIN (ISTODAX): CYCLIC TETRAPEPTIDES AND DESPEPTIDES 70
      • Market Overview 71
      • Market Revenue 71
      • TABLE 9 GLOBAL ROMIDEPSIN MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 72
      • FIGURE 25 GLOBAL ROMIDEPSIN MARKET BY REGION, 2011-2018 ($ MILLIONS) 72
    • MARKET SHARE 72
    • TABLE 10 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY TYPE,2012 (%) 73
    • FIGURE 26 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY TYPE, 2012 (%) 73
  • MARKET BY REGION 73
    • MARKET OVERVIEW 73
    • MARKET REVENUE 75
    • TABLE 11 HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 76
    • FIGURE 27 HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, 2011-2018 ($ MILLIONS) 76
    • MARKET SHARE 76
    • TABLE 12 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY REGION, 2012 ($ MILLIONS) 77
    • FIGURE 28 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY REGION, 2012 ($ MILLIONS) 77
  • PROSPECTIVE FUTURE HISTONE DEACETYLASE INHIBITORS MARKET 77
  • INDUSTRY STRUCTURE 78
  • TABLE 13 LEADING HISTONE DEACETYLASE INHIBITOR MANUFACTURERS AND SUPPLIERS BY TYPE 78
  • MARKET SHARES 79
  • TABLE 14 HISTONE DEACETYLASE INHIBITOR MANUFACTURERS BY MARKET SHARE, 2012 (%) 79
  • FIGURE 29 HISTONE DEACETYLASE INHIBITOR MANUFACTURERS BY MARKET SHARE, 2012 (%) 80

CHAPTER 7 MARKET BY APPLICATION 82

  • TABLE 15 HISTONE DEACETYLASE INHIBITOR TYPES BY APPLICATION 82
  • TABLE 16 HISTONE DEACETYLASE INHIBITOR COMBINATIONS WITH THERAPIES BY APPLICATION 83
  • MARKET BY APPLICATION 84
    • CUTANEOUS T-CELL LYMPHOMAS 84
    • PERIPHERAL T-CELL LYMPHOMAS 84
    • MARKET OVERVIEW 85
    • MARKET REVENUE 86
    • TABLE 17 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY DISEASE TYPE, THROUGH 2018 ($ MILLIONS) 87
    • FIGURE 30 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY DISEASE TYPE, 2011-2018 ($ MILLIONS) 87
    • MARKET SHARE 88
    • TABLE 18 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY DISEASE TYPE, 2012 (%) 88
    • FIGURE 31 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY DISEASE TYPE, 2012 (%) 88
  • PROSPECTIVE APPLICATIONS FOR HISTONE DEACETYLASE INHIBITORS 88
    • CANCER 89
    • NEURODEGENERATIVE AND CENTRAL NERVOUS SYSTEM DISEASES 89
    • INFLAMMATORY DISEASES 90
    • CARDIAC AILMENTS 91
    • HIV AND AIDS 91
    • OTHERS 91
  • RESEARCH AND DEVELOPMENT 92
  • TABLE 19 HISTONE DEACETYLASE INHIBITOR FUNDING ($ MILLIONS) 93

CHAPTER 8 PATENT ANALYSIS 95

  • PATENTS BY YEAR 96
  • TABLE 20 PATENTS GRANTED, 2011-OCTOBER 2013 96
  • FIGURE 32 PATENTS GRANTED, 2011-OCTOBER 2013 96
  • PATENTS BY HISTONE DEACETYLASE INHIBITOR CATEGORY 97
  • TABLE 21 HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013 97
  • FIGURE 33 HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013 98
  • PATENTS BY HISTONE DEACETYLASE INHIBITORS TYPE 98
    • PATENTS BY HYDROXAMIC ACID 98
    • TABLE 22 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY TYPE, 2011-OCTOBER 2013 99
    • FIGURE 34 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY TYPE, 2011-OCTOBER 2013 99
    • CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS 100
    • TABLE 23 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY TYPE, 2011-OCTOBER 2013 100
    • BENZAMIDE PATENTS 100
    • TABLE 24 BENZAMIDE PATENTS BY TYPE, 2011-OCTOBER 2013 100
    • ALIPHATIC ACID COMPOUND PATENTS 101
    • TABLE 25 ALIPHATIC ACID COMPOUND PATENTS BY TYPE, 2011-OCTOBER 2013 101
    • OTHER HISTONE DEACETYLASE INHIBITOR PATENTS 101
    • TABLE 26 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013 101
  • PATENTS BY COUNTRY 102
    • HYDROXAMIC ACID 102
    • TABLE 27 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY COUNTRY, 2011-OCTOBER 2013 102
    • TABLE 28 HYDROXAMIC ACID OR HYDROXAMATES PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%) 103
    • CYCLIC TETRAPEPTIDES AND DEPSIPEPTIDES 103
    • TABLE 29 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY COUNTRY, 2011-OCTOBER 2013 103
    • TABLE 30 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%) 104
    • BENZAMIDES 104
    • TABLE 31 BENZAMIDE PATENTS BY COUNTRY, 2011-OCTOBER 2013 104
    • TABLE 32 BENZAMIDE PATENT SHARES BY COUNTRY, 2011-OCT 2013 (%) 105
    • ALIPHATIC ACID COMPOUNDS 105
    • TABLE 33 ALIPHATIC ACID COMPOUND PATENTS BY COUNTRY, 2011-OCTOBER 2013 105
    • TABLE 34 ALIPHATIC ACID COMPOUND PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%) 106
    • OTHER HISTONE DEACETYLASE INHIBITORS 106
    • TABLE 35 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY COUNTRY, 2011-OCTOBER 2013 106
    • TABLE 36 OTHER HISTONE DEACETYLASE INHIBITOR PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%) 107
  • PATENTS BY COMPANY 107
    • HYDROXAMIC ACIDS 107
    • TABLE 37 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY COMPANY, 2011-OCTOBER 2013 107
    • CYCLIC TETRAPEPTIDES AND DEPSIPEPTIDES 108
    • TABLE 38 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY COMPANY, 2011-OCTOBER 2013 108
    • BENZAMIDES 108
    • TABLE 39 BENZAMIDE PATENTS BY COMPANY, 2011-OCTOBER 2013 109
    • ALIPHATIC ACID COMPOUNDS 109
    • TABLE 40 ALIPHATIC ACID COMPOUND PATENTS BY COMPANY, 2011-OCTOBER 2013 109
    • OTHER HISTONE DEACETYLASE INHIBITORS 109
    • TABLE 41 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY COMPANY, 2011-OCTOBER 2013 110
      • PATENTS BY ASSIGNEE 110
    • HYDROXAMIC ACIDS 110
    • TABLE 42 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 110
    • CYCLIC TETRAPEPTIDES AND DEPSIPEPTIDES 111
    • TABLE 43 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 111
    • BENZAMIDES 111
    • TABLE 44 BENZAMIDE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 111
    • ALIPHATIC ACID COMPOUNDS 112
    • TABLE 45 ALIPHATIC ACID COMPOUND PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 112
    • OTHER HISTONE DEACETYLASE INHIBITORS 112
    • TABLE 46 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 112

CHAPTER 9 CURRENT SITUATION 114

  • RESEARCH AND PROGRESS 114
  • NEW TECHNOLOGIES AND PLATFORMS IN HISTONE DEACETYLASE DEVELOPMENT 115
    • CANCERNAV 115
    • CHEMOGENOMIC-BASED DISCOVERY PLATFORM 115
    • ESTERASE-SENSITIVE MOTIF TECHNOLOGY 115
    • BIOLUMINESCENT HISTONE DEACETYLASE ASSAY 116
  • FACTORS AFFECTING THE HISTONE DECAETYLASE MARKET 116
  • CURRENT DRIVERS OF HISTONE DEACETYLASE MARKET 116
  • COLLABORATIONS AND ACQUISITIONS 117

CHAPTER 10 COMPANY PROFILES 120

  • 4SC 120
  • ACETYLON PHARMACEUTICALS INC. 122
  • ARNO THERAPEUTICS INC. 124
  • ASAN MEDICAL CENTER 124
  • ASTELLAS PHARMA INC. 125
  • ASTRAZENECA PLC 126
  • CELGENE CORPORATION 127
  • CELLCEUTIX CORPORATION 128
  • CELLERON THERAPEUTICS LTD. 129
  • CHROMA THERAPEUTICS LTD. 130
  • COLUMBIA UNIVERSITY 130
  • CRYSTALGENOMICS INC. 131
  • CURIS INC. 131
  • CYCLACEL PHARMACEUTICALS 133
  • CYCLEX CO. LTD. 133
  • DIAXONHIT GROUP 134
  • ENVIVO PHARMACEUTICALS 134
  • GENENTECH INC. 135
  • GEORGETOWN UNIVERSITY 135
  • GEORGIA TECH RESEARCH CORP. 136
  • GILEAD SCIENCES INC. 136
  • IMPERIAL INNOVATIONS LTD. 137
  • ITALFARMACO S.P.A. 138
  • JANSSEN PHARMACEUTICA NV 138
  • KARUS THERAPEUTICS LIMITED 139
  • LES LABORATOIRES SERVIER 139
  • LIXTE BIOTECHNOLOGY HOLDINGS INC. 140
  • MAYO CLINIC 140
  • MEI PHARMA INC 141
  • MEMORIAL SLOAN-KETTERING CANCER CENTER 142
  • MERCK & CO. INC. 142
  • MIRATI THERAPEUTICS 143
  • NATIONAL CANCER INSTITUTE 144
  • NATIONAL COMPREHENSIVE CANCER NETWORK 145
  • NATUREWISE BIOTECH & MEDICALS CORPORATION 145
  • NOVARTIS INTERNATIONAL AG 146
  • OCEANYX PHARMACEUTICALS INC. 147
  • OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER 147
  • ONCOLYS BIOPHARMA INC. 148
  • PFIZER 148
  • PHARMACYCLICS 149
  • PROMEGA CORPORATION 149
  • REPLIGEN CORPORATION 150
  • ROSWELL PARK CANCER INSTITUTE 151
  • SHAPE PHARMACEUTICALS 152
  • SHENZHEN CHIPSCREEN BIOSCIENCES 153
  • SPECTRUM PHARMACEUTICALS 154
  • SYNDAX PHARMACEUTICALS INC. 155
  • TITAN PHARMACEUTICALS INC. 156
  • TOPOTARGET A/S 156
  • UNIVERSITY OF ILLINOIS: OFFICE OF TECHNOLOGY MANAGEMENT 157
  • UNIVERSITY OF SOUTHAMPTON HIGHFIELD 158
  • UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER 159
  • YAKULT HONSHA CO. LTD. 160

CHAPTER 11 ABBREVIATIONS 162

LIST OF TABLES

  • SUMMARY TABLE GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 8
  • TABLE 1 HISTONE DEACETYLASE CLASSIFICATION 13
  • TABLE 2 EMERGING TARGETS FOR HISTONE DEACETYLASES INHIBITORS, BY HDI CLASS 33
  • TABLE 3 DEVELOPMENT STAGES FOR HISTONE DEACETYLASE INHIBITORS 51
  • TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES, OCTOBER 2013 52
  • TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS COMBINATION THERAPIES, OCTOBER 2013 54
  • TABLE 6 ONGOING TRIALS FOR MAJOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES AND COMBINATION THERAPIES, OCTOBER 2013 62
  • TABLE 7 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY TYPE, THROUGH 2018 ($ MILLIONS) 67
  • TABLE 8 GLOBAL VORINSTAT MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 70
  • TABLE 9 GLOBAL ROMIDEPSIN MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 72
  • TABLE 10 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY TYPE,2012 (%) 73
  • TABLE 11 HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 76
  • TABLE 12 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY REGION, 2012 ($ MILLIONS) 77
  • TABLE 13 LEADING HISTONE DEACETYLASE INHIBITOR MANUFACTURERS AND SUPPLIERS BY TYPE 78
  • TABLE 14 HISTONE DEACETYLASE INHIBITOR MANUFACTURERS BY MARKET SHARE, 2012 (%) 79
  • TABLE 15 HISTONE DEACETYLASE INHIBITOR TYPES BY APPLICATION 82
  • TABLE 16 HISTONE DEACETYLASE INHIBITOR COMBINATIONS WITH THERAPIES BY APPLICATION 83
  • TABLE 17 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY DISEASE TYPE, THROUGH 2018 ($ MILLIONS) 87
  • TABLE 18 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY DISEASE TYPE, 2012 (%) 88
  • TABLE 19 HISTONE DEACETYLASE INHIBITOR FUNDING ($ MILLIONS) 93
  • TABLE 20 PATENTS GRANTED, 2011-OCTOBER 2013 96
  • TABLE 21 HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013 97
  • TABLE 22 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY TYPE, 2011-OCTOBER 2013 99
  • TABLE 23 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY TYPE, 2011-OCTOBER 2013 100
  • TABLE 24 BENZAMIDE PATENTS BY TYPE, 2011-OCTOBER 2013 100
  • TABLE 25 ALIPHATIC ACID COMPOUND PATENTS BY TYPE, 2011-OCTOBER 2013 101
  • TABLE 26 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013 101
  • TABLE 27 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY COUNTRY, 2011-OCTOBER 2013 102
  • TABLE 28 HYDROXAMIC ACID OR HYDROXAMATES PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%) 103
  • TABLE 29 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY COUNTRY, 2011-OCTOBER 2013 103
  • TABLE 30 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%) 104
  • TABLE 31 BENZAMIDE PATENTS BY COUNTRY, 2011-OCTOBER 2013 104
  • TABLE 32 BENZAMIDE PATENT SHARES BY COUNTRY, 2011-OCT 2013 (%) 105
  • TABLE 33 ALIPHATIC ACID COMPOUND PATENTS BY COUNTRY, 2011-OCTOBER 2013 105
  • TABLE 34 ALIPHATIC ACID COMPOUND PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%) 106
  • TABLE 35 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY COUNTRY, 2011-OCTOBER 2013 106
  • TABLE 36 OTHER HISTONE DEACETYLASE INHIBITOR PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%) 107
  • TABLE 37 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY COMPANY, 2011-OCTOBER 2013 107
  • TABLE 38 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY COMPANY, 2011-OCTOBER 2013 108
  • TABLE 39 BENZAMIDE PATENTS BY COMPANY, 2011-OCTOBER 2013 109
  • TABLE 40 ALIPHATIC ACID COMPOUND PATENTS BY COMPANY, 2011-OCTOBER 2013 109
  • TABLE 41 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY COMPANY, 2011-OCTOBER 2013 110
  • TABLE 42 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 110
  • TABLE 43 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 111
  • TABLE 44 BENZAMIDE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 111
  • TABLE 45 ALIPHATIC ACID COMPOUND PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 112
  • TABLE 46 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY ASSIGNEE, 2011-OCTOBER 2013 112

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, 2011-2018 ($ MILLIONS) 8
  • FIGURE 1 HYDROXAMIC ACID GENERAL STRUCTURE 15
  • FIGURE 2 TRICHOSTATIN A ACID STRUCTURE 15
  • FIGURE 3 TRAPOXIN B STRUCTURE 17
  • FIGURE 4 ROMIDEPSIN STRUCTURE 17
  • FIGURE 5 BENZAMIDE STRUCTURE 18
  • FIGURE 6 VALPROIC ACID STRUCTURE 19
  • FIGURE 7 SODIUM VALPROATE STRUCTURE 20
  • FIGURE 8 SODIUM PHENYLBUTERATE STRUCTURE 20
  • FIGURE 9 SODIUM BUTYRATE STRUCTURE 21
  • FIGURE 10 PIVANEX STRUCTURE 23
  • FIGURE 11 VORINOSTAT STRUCTURE 23
  • FIGURE 12 BELINOSTAT STRUCTURE 25
  • FIGURE 13 DACINOSTAT STRUCTURE 25
  • FIGURE 14 PANOBINOSTAT STRUCTURE 26
  • FIGURE 15 GIVINOSTAT STRUCTURE 26
  • FIGURE 16 PRACINOSTAT STRUCTURE 27
  • FIGURE 17 ABEXINOSTAT STRUCTURE 28
  • FIGURE 18 QUISINOSTAT STRUCTURE 29
  • FIGURE 19 RESMINOSTAT STRUCTURE 29
  • FIGURE 20 ENTINOSTAT STRUCTURE 30
  • FIGURE 21 CI994 STRUCTURE 31
  • FIGURE 22 MOCETINOSTAT STRUCTURE 31
  • FIGURE 23 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY TYPE, 2011-2018 ($ MILLIONS) 68
  • FIGURE 24 GLOBAL VORINSTAT MARKET BY REGION, 2011-2018 ($ MILLIONS) 70
  • FIGURE 25 GLOBAL ROMIDEPSIN MARKET BY REGION, 2011-2018 ($ MILLIONS) 72
  • FIGURE 26 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY TYPE, 2012 (%) 73
  • FIGURE 27 HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, 2011-2018 ($ MILLIONS) 76
  • FIGURE 28 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY REGION, 2012 ($ MILLIONS) 77
  • FIGURE 29 HISTONE DEACETYLASE INHIBITOR MANUFACTURERS BY MARKET SHARE, 2012 (%) 80
  • FIGURE 30 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY DISEASE TYPE, 2011-2018 ($ MILLIONS) 87
  • FIGURE 31 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY DISEASE TYPE, 2012 (%) 88
  • FIGURE 32 PATENTS GRANTED, 2011-OCTOBER 2013 96
  • FIGURE 33 HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013 98
  • FIGURE 34 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY TYPE, 2011-OCTOBER 2013 99
Back to Top